Filing summary
Entity and period: The supplied filing is Parametric Sound Corporation’s Form 10-K for the fiscal year ended September 30, 2012, not a Turtle Beach Corp filing. It describes a small audio-technology company developing and selling HyperSound directional-audio products and pursuing technology licensing.
Financial performance and position
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $233,649 | $79,167 |
| Gross profit / margin | $113,507 / 49% | $43,643 / 55% |
| Operating expenses | $4,587,752 | $1,220,319 |
| Operating loss | $(4,474,245) | $(1,176,676) |
| Net loss | $(4,462,182) | $(1,484,458) |
| Net loss per share | $(0.85) | $(0.44) |
| Cash used in operating activities | $(2,752,165) | $(992,519) |
- Revenue increased 180% year over year, from a small base; substantially all revenue was product-related, with no licensing revenue recognized.
- Gross margin fell 6 percentage points. Management cautioned that limited sales and manufacturing history makes historical margins a poor guide to future margins.
- At September 30, 2012, cash and cash equivalents were $5,527,647; current assets were $6,073,550 and current liabilities were $313,212. Management said cash reserves were expected to fund operations for the next 12 months.
- There was no debt reported on the September 30, 2012 balance sheet. The company had raised about $8.0 million net in a March–April 2012 stock offering; cash also included $192,338 from option exercises.
- Total assets were $7,565,323 and stockholders’ equity was $7,252,111. The company reported recurring losses and negative operating cash flow.
Changes, outlook, and notable items
- Revenue rose from $79,167 to $233,649, but net loss nearly tripled as operating expenses increased sharply. FY 2012 expenses included $1,686,909 of non-cash share-based compensation, versus $188,311 in FY 2011; research and development expense increased to $1,340,054 from $647,994.
- The company shifted strategy toward licensing in early 2012 while continuing digital-signage product sales. It reported more than 20 nondisclosure agreements with prospective partners and one Epsilon Electronics development-stage license. That agreement had generated no revenue or payments; potential manufacturing and royalties were conditional, and revenue was not assured.
- Management expected higher product sales and additional licensing or co-development arrangements in fiscal 2013, but could not predict sales levels or licensing timing. No quantified financial guidance was provided.
- A related-party transaction transferred technology and intellectual property from Syzygy Licensing, owned by the company’s president and CFO. Consideration was 300,000 shares valued at $975,000 plus $250,000 cash, and the transaction ended future royalty obligations.
- Three customers contributed 30%, 16%, and 16% of FY 2012 revenue; one customer accounted for 98% of year-end receivables. The company also relied on a single supplier for key piezo film.
- Management identified risks from continued losses, possible additional financing needs, unproven licensing, customer concentration, supplier dependence, competition, product performance, intellectual-property protection, and regulatory clearance for planned hearing-related products. A new health subsidiary was formed in October 2012; the company was preparing, but had not assured, an FDA 510(k) filing.
- The company completed a 1-for-5 reverse stock split and a Nasdaq listing in 2012. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation because the company qualified as a smaller reporting company.
Investor facts to verify
- Confirm the intended issuer: this filing is for Parametric Sound Corporation, not Turtle Beach Corp.
- Review the audited financial statements and cash-flow assumptions supporting management’s 12-month liquidity estimate, particularly given operating cash use of $2.75 million and limited revenues.
- Check whether the Epsilon development project advanced to manufacturing, generated fees or royalties, or remained contingent after the filing date.
- Assess customer concentration, the single-source piezo-film supply risk, and any changes in gross margins, inventory reserves, or warranty costs.
- Review the related-party Syzygy intellectual-property purchase, its valuation and approval, and the potential dilution from outstanding options and warrants.
- Verify subsequent progress on the health-device regulatory pathway and any associated development, testing, or financing costs.